42.  Koptyra M, Gupta S, Nevalainen MT: Transcription Factor Stat5a/b in Prostate Cancer. In: Int. J. Biochemistry and Cell Biology, Molecules In Focus, 2010.

 

41.  Gupta S, Liao Z, Nevalainen MT. Jak2-Stat5 Pathway in Prostate Cancer. In: The Encyclopedia of Cancer Targets. Marshall JL, Weiner L, Gelmann E, Kaufman H, Wellstein A (Eds). Springer Verlag, 2010.

 

40.  Vogiatzi P, Nevalainen MT. Jak2/Stat5 Signaling Axis and Novel Therapeutic Strategies in Prostate Cancer. In: Cutting Edge Therapies for Cancer in 21st Century. Claudio PP (Ed), Bentham Science Publishers Ltd, 2010.

 

39.  Dagvadorj A, Tan SH, Xie J, Nurmi M, Alanen K, Rui H, Mirtti T, Nevalainen MT. N-Terminal truncation of Stat5a/b circumvents PIAS3-mediated inhibition of Stat5 in prostate cancer cells. In review, Journal of Biological Chemistry, 2010.

 

38.  Liao Z, Shen F, Dagvadorj A, Abdulghani J, Leiby B, Tan S, Nevalainen MT. Liganded glucocoticoid receptor functionally interacts with transcription factor Stat5 in human prostate cancer cells and promotes prostate xenograft tumor growth. Submitted, Endocrinology, 2010.

 

37.  Gu L, Zhu XH, Visakorpi T, Alanen K, Mirtti T, Bocker Edmonston T, Nevalainen MT. Activating Mutation (V617F) in the Tyrosine Kinase Jak2 is absent in Locally-confined or Castration-Resistant Prostate Cancer. In Review, Cellular Oncology, 2010.

 

36.  Gu L, Dagvadorj A, Lutz J, Leiby B, Bonucelli G, Lisanti M, Addya S, Fortina P, Dasgupta A, Hyslop T, Rhimm J, Bubendorf L, Nevalainen MT. Transcription Factor Stat3 Stimulates Metastatic Behavior of Human Prostate Cancer Cells In Vivo While Stat5 Has a Preferential Role in the Promotion of Prostate Cancer Cell Viability and Tumor Growth. In Press, American Journal of Pathology, Apr;176(4):1959-72 2010. Featured in Uro.Today.

 

35.  Gu, L, Vogiatzi PV, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby C, Dasgupta A, Hyslop T, Bubendorf L, Mirtti TK, Nevalainen MT. Stat5 Promotes Metastatic Behavior of Human Prostate Cancer Cells In Vitro and In Vivo. In Press, Endocrine-Related Cancer, 2010.

 

34.  Liao Z, Lutz J, Nevalainen MT. Transcription Factor Stat5a/b as a Therapeutic Target Protein for Prostate Cancer. International Journal of Biochemistry and Cell Biology, 42:186-192, 2010.

 

33.  Dagvadorj A, Tan SH, Cavalli L, Haddad B, Nevalainen MT. Androgen-dependent and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor.  Clinical Cancer Research, 14: 6062-6072, 2008.

 

32.  Tan SH and Nevalaine MT Transcription factor Stat5 in breast and prostate cancer.  Endocrine Related Cancer, 15:367-390, 2008.

 

31.  Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonucelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT.  Transcription factor Stat3 promotes metastatic behavior of prostate cancer.  American Journal of Pathology, 172:1717-1728, 2008.

 

30.  Dagvadorj A, Kirken RA, Karras J, Nevalainen MT. Transcription factor Stat5 promotes growth of human prostate cancer cells in vivo.  Clinical Cancer Research, 14:1317-1324, 2008.

 

29.  Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT.  Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.  Cancer Research, 68:1-13, 2008.

 

28.  Powell M, Lisanti MP, Nevalainen MT, Wang C, Pestell RG. Androgen receptor epigenetic modification and acetylation regulate prostate cellular growth. In: Pestell RG and Nevalainen MT (Eds.) Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies. New York: Humana Press; 2008. p. 147 – 162.

 

27.  Culig Z, Pestell RG, Nevalainen MT.  Transcription factors Stat5 and Stat3: Key survival factors for prostate cancer cells.  In: Pestell RG and Nevalainen MT (Eds.) Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies. New York: Humana Press; 2008. p. 257 – 290.

 

26.  Pestell RG and Nevalainen MT.  (Eds.) Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies. New York: Humana Press; 2008.

 

25.  Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen MT, Fu M, Pestell RG.  The functional significance of nuclear receptor acetylation.  Steroids, 72:221-230, 2007.

 

24.  Dagvadorj A, Collins S, Jomain J, Abdulghani J, Karras J, Zellweger T, Li H, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT.  Autocrine prolactin promotes prostate cancer cell growth via Jak2-Stat5 signaling pathway.  Endocrinology, 148:3089-3101, 2007.

 

23.  LeBaron MJ, Ahonen TJ, Nevalaine n MT, Rui H.  In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays.  Endocrinology, 148:989-1008, 2007.

 

22.  Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT.  Activation of signal transducer and activator of transcription-5 (Stat5) in prostate cancer predicts early recurrence.  Clinical Cancer Research, 11:5863-5868, 2005.

 

21.  Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H.  Transcription factor Stat5 stimulates homotypic adhesion and inhibits invasive characteristics of human breast cancer cells.  Oncogene, 24:746-760, 2005.

 

20.  Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EE, Zhang J, Nurmi M, Singh B, Martikainen P, Nevalainen MT.  Activation of signal transducer and activator of transcription 5 (Stat5) in human prostate cancer is associated with high histological grade. Cancer Research, 64:4774-4782, 2004.

 

19.  Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Konenen H, Sauter G, Rui H.  Transcription factor Stat5 activation and breast cancer prognosis.  Journal of Clinical Oncology, 22(11): 2053-2060, 2004.

 

18.  Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT.  Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells.  Journal of Biological Chemistry, 278:27287-27292, 2003.

 

17.  Rui H, Nevalainen MT.  Prolactin.  In: Thomson A and Lotze MT (Eds.) Cytokine Handbook, 4^th Edition.  London: Academic Press; 2003. p. 113-146.

 

16.  Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription Stat5 in nonpregnant mouse and human breast epithelium.  Molecular Endocrinology, 16:1108-1124, 2002.

 

15.  Xie J, LeBaron MJ, Nevalaine n MT, Rui H.  Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells.  Journal of Biological Chemistry, 277:14020-14030, 2002.

 

14.  Ahonen T, Harkonen PL, Rui H, Nevalainen MT. Prolactin signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro.  Endocrinology, 143:228-238, 2002.

 

13.  Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon G, Hennighausen L, Kirken Ra, Rui H.  Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression.  Molecular and Cellular Endocrinology, 183:151-163, 2001.

 

12.  Valve E, Nevalainen MT, Nurmi M, Martikainen P, Harkonen P.  Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia and prostate cancer.  Laboratory Investigation, 81:815-826, 2001.

 

11. Uotila P, Valve E, Martikainen P, Nevalainen MT, Nurmi M, Harkonen P.  Increased expression of cyclo-oxygenase-2 and nitric oxide synthase-2 in human prostate cancer.  Urological Research, 29:25-28, 2001.

 

10.  Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar S, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H.  Epithelial defect in prostates of Stat5a-deficient mice.  Laboratory Investigation, 80:993-1006, 2000.

 

9.  Ahonen T, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT.  Prolactin is a survival factor in androgen-deprived rat dorsal and lateral prostate in organ culture.  Endocrinology, 140:5412-5421, 1999.

 

8.  Kallajoki M, Alanen KA, Nevalaine n MT, Nurmi M, Nevalainen TJ.  Expression of group II phospholipase A2 in male reproductive organs and male genital tumors.  Prostate, 35:263-272, 1998.

 

7.  Nevalainen MT, Valve EM, Ahonen TA, Yagi A, Paranko J, Härkönen PL.  Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture.  The FASEB Journal, 11: 1297-1308, 1997.

 

6.  Nevalainen MT, Valve EM, Ingleton PM, Martikainen P, Nurmi M, Härkönen PL.  Prolactin receptors are expressed and functioning in human prostate.  Journal of Clincal Investigation, 99:618-627, 1997.

 

5.  Nevalainen MT, Valve EM, Ingletown P, Härkönen PL.  Expression and hormone regulation of prolactin receptor in rat dorsal and lateral prostate.  Endocrinology, 137:3078-3088, 1996.

 

4.  Nevalainen MT, Härkönen PL, Valve EM, Ping W, Nurmi M, Martikainen PM.  Hormone regulation of human prostate in organ culture.  Cancer Research, 53:5199-5207, 1993.

 

3.  Martikainen P, Nevalaine n MT, Härkönen PL.  Organ cultures of rat and human prostate. In: Kumar A (Ed.) Techniques in reproductive biomedicine. A method manual. New Dehli: B.I. Churchill Livingstone, 1993. p. 666-680.

 

2.  Väänänen HK, Valve EM, Mäkelä, SI, Nevalainen MT, Härkönen PL. Hormone regulation of carbonic anhydrase II expression.  In: Botre, Frass G, Storey BT (Eds.) Carbonic anhydrase: from Biochemistry and Genetics to Physiology and Clinical Chemistry. Weinheim, Germany: VCH Verlagsgesellchaft, 1991. p. 345-351.

 

1.  Nevalainen MT, Valve EM, Mäkelä, SI, Bläuer M, Tuohimaa PJ, Härkönen PL.  Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture.  Endocrinology, 129:612-622, 1991.